[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634261":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":25,"centralContacts":30,"locations":35,"responsibleParty":48,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":72,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Peginterferon α-2b based treatment group",null,[12],"Drug: PEG IFNα-2b monotherapy or combination therapy with NAs",{"label":14,"type":10,"description":10,"interventionNames":15},"NAs monotherapy group",[16],"Drug: NAs monotherapy group",[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DRUG","PEG IFNα-2b monotherapy or combination therapy with NAs","Peginterferon α-2b injection, 180mcg, s.c, once a week, for 48 weeks.If HBV DNA is below the lower limit of detection at baseline (highly sensitive assay is recommended), PEG IFNα-2b monotherapy will be administered.",[9],{"type":19,"name":14,"description":21,"armGroupLabels":24,"otherNames":10},[14],[26],{"name":27,"affiliation":28,"role":29},"Qing Xie","Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","PRINCIPAL_INVESTIGATOR",[31],{"name":27,"role":32,"phone":33,"phoneExt":10,"email":34},"CONTACT","13651804273","xieqingrjh@163.com",[36],{"facility":28,"status":10,"city":37,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Shanghai","China","CN",{"type":41,"coordinates":42},"Point",[43,44],121.45806,31.22222,{"lat":44,"lon":43},[47],{"name":27,"role":32,"phone":33,"phoneExt":10,"email":34},{"type":49,"investigatorFullName":50,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","xieqing","100634261","a-study-on-the-pursuit-of-sustained-clearance-of-hbsag-in-chronic-hepatitis-bchb-patients-with-previous-interferon-treatment-using-pegylated-interferon-alpha-100634261",false,"NCT07537387","A Study on the Pursuit of Sustained Clearance of HBsAg in Chronic Hepatitis B(CHB) Patients With Previous Interferon Treatment Using Pegylated Interferon Alpha","A Prospective, Non-Randomized, Multicenter Study of Peginterferon Alfa for Pursuing Sustained Hepatitis B Surface Antigen(HBsAg) Clearance in Interferon-Pretreated Patients With Chronic Hepatitis B","Inclusion Criteria:\n\n* • Voluntary participation and ability to understand and provide written informed consent.\n\n  * Age 18-65 years (inclusive), either gender.\n  * Documented HBsAg positivity for at least 6 months, or other evidence confirming chronic hepatitis B (CHB).\n  * Prior interferon therapy before enrollment (treatment discontinuation ≥ 3 months), with HBsAg level at the end of prior treatment reduced by ≥ 50% from baseline.\n  * HBsAg ≤ 500 IU\u002FmL at screening, and HBsAg rebound at screening not exceeding 50% of the baseline HBsAg level during the first-round interferon therapy.\n  * Negative pregnancy test within 24 hours prior to the first dose (for women of childbearing potential); all subjects (male and female) must use effective contraceptive measures during the study.\n\nExclusion Criteria:\n\n* • Pregnant or lactating women, or subjects with a pregnancy plan during the study period.\n\n  * Subjects with neuropsychiatric disorders, in particular a history of depression, anxiety, mania, schizophrenia, or a family history of psychiatric disorders (especially a history of depression or depressive tendency).\n  * Concurrent active infection with hepatitis A, hepatitis C, hepatitis E and\u002For HIV, or chronic liver disease due to other causes (e.g., alcoholic hepatitis, drug-induced liver injury, autoimmune liver disease, etc.).\n  * Evidence of acute severe liver damage: e.g., ALT \\> 10 × ULN, or marked ALT elevation accompanied by significant hyperbilirubinemia.\n  * Evidence of decompensated liver disease: e.g., ascites, esophagogastric variceal bleeding, sepsis, hepatic encephalopathy, hepatorenal syndrome, etc.; or prior evidence of decompensated cirrhosis.\n  * Evidence of hepatocellular carcinoma (HCC), or AFP \\> 1 × ULN.\n  * Renal diseases: acute or chronic nephritis, renal insufficiency, nephrotic syndrome, etc.; or serum creatinine \\> 1 × ULN at screening.\n  * Neutrophil count \\\u003C 1.5 × 10⁹\u002FL, platelet count \\\u003C 90 × 10⁹\u002FL, or serum phosphorus \\\u003C 0.8 mmol\u002FL during the screening period.\n  * Autoimmune diseases (e.g., psoriasis, systemic lupus erythematosus, etc.), endocrine disorders (e.g., thyroid diseases, diabetes, etc.), hypertension poorly controlled by prescription medications (blood pressure ≥ 140\u002F90 mmHg), a history of severe heart disease (especially poorly controlled within 6 months), severe retinopathy or other serious ophthalmologic diseases, or other organic lesions or dysfunction of vital organs.\n  * Subjects planning to undergo or having previously undergone organ transplantation.\n  * Subjects with hypersensitivity to the investigational product or its excipients, or meeting any contraindication listed in the prescribing information of the investigational product.\n  * Other conditions deemed inappropriate for enrollment by the investigator","ALL","18 Years","65 Years",{"count":62,"type":63},10000,"ESTIMATED","OBSERVATIONAL","This is a real-world, prospective, multicenter, non-randomized, controlled study. It aims to investigate the efficacy and safety of pegylated interferon α-2b (PEG IFN α-2b) monotherapy versus its combination with nucleos(t)ide analogs (NAs) regarding hepatitis B surface antigen (HBsAg) clearance in interferon-experienced patients with chronic hepatitis B (CHB). Subjects will receive either interferon-based therapy or NAs monotherapy based on their personal willingness and physicians' professional recommendations, with a uniform 48-week treatment course for all enrolled patients.",[67],"Chronic Hepatitis b",[69,70,71],"CHB","Peginterferon","retreatment","NOT_YET_RECRUITING","2026-04-15",{"date":75,"type":76},"2026-04-17","ACTUAL",{"date":78,"type":63},"2026-04-30",{"date":80,"type":63},"2030-12-31",{"name":50,"class":6},1]